Sepsis: Pathophysiology, Diagnosis and Therapy
A special issue of Antibiotics (ISSN 2079-6382).
Deadline for manuscript submissions: closed (10 December 2019) | Viewed by 36234
Special Issue Editor
Interests: human microbiota; probiotics; H. pylori; SARS-CoV-2; oncogenesis; history of medicine
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Sepsis is currently defined as the presence of a systemic inflammatory response syndrome (SIRS) in the setting of infection. Severe sepsis is defined as sepsis with evidence of end-organ dysfunction as a result of hypoperfusion, ultimately leading to septic shock and death if with persistent hypotension despite fluid resuscitation and resulting tissue hypoperfusion.
Mortality is still now up to 30%, and therapy requires an early detection of the causes of the infection and very good knowledge about its pathophysiology to prevent complications and death. During the last decade, a lot of data have been acquired about this issue, but antibiotic therapy still remains the backbone of the patients' treatment. On the other hand, during the last 20 years no new antibiotics have been invented, and the number of antibiotic resistant microrganisms is continuously increasing. So we need a new, updated diagnostic protocol including new biomarkers, and new therapies to lower the medical expenses and improve prognosis for septic patients.
Dr. Luigi Santacroce
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Sepsis
- gram negative bacteria
- microrganisms
- antibiotics
- antibiotic resitant microrganisms
- SIRS
- immune system
- immune response
- immune anergy
- inflammation
- coagulation
- coagulopathy
- microvascular thrombosis
- multiple organ dysfunction
- septic shock
- death
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.